Sárközy Márta, Fekete Veronika, Szűcs Gergő, Török Szilvia, Szűcs Csilla, Bárkányi Judit, Varga Zoltán V, Földesi Imre, Csonka Csaba, Kónya Csaba, Csont Tamás, Ferdinandy Péter
Pharmahungary Group, Szeged, Hungary.
BMC Endocr Disord. 2014 Aug 26;14:72. doi: 10.1186/1472-6823-14-72.
Although multivitamin products are widely used as dietary supplements to maintain health or as special medical food in certain diseases, the effects of these products were not investigated in diabetes mellitus, a major cardiovascular risk factor. Therefore, here we investigated if a preparation of different minerals, vitamins, and trace elements (MVT) for human use affects the severity of experimental diabetes.
Two days old neonatal Wistar rats from both genders were injected with 100 mg/kg of streptozotocin or its vehicle to induce diabetes. At week 4, rats were fed with an MVT preparation or vehicle for 8 weeks. Well established diagnostic parameters of diabetes, i.e. fasting blood glucose and oral glucose tolerance test were performed at week 4, 8 and 12. Moreover, serum insulin and blood HbA1c were measured at week 12.
An impaired glucose tolerance has been found in streptozotocin-treated rats in both genders at week 4. In males, fasting blood glucose and HbA1c were significantly increased and glucose tolerance and serum insulin was decreased at week 12 in the vehicle-treated diabetic group as compared to the vehicle-treated non-diabetic group. All of the diagnostic parameters of diabetes were significantly improved by MVT treatment in male rats. In females, streptozotocin treatment resulted in a less severe prediabetic-like phenotype as only glucose tolerance and HbA1c were altered by the end of the study in the vehicle-treated diabetic group as compared to the vehicle-treated non-diabetic group. MVT treatment failed to improve the diagnostic parameters of diabetes in female streptozotocin-treated rats.
This is the first demonstration that MVT significantly attenuates the progression of diabetes in male rats with chronic experimental diabetes. Moreover, we have confirmed that females are less sensitive to STZ-induced diabetes and MVT preparation did not show protection against prediabetic state. This may suggest a gender difference in the pathogenesis of diabetes.
尽管多种维生素产品被广泛用作膳食补充剂以维持健康，或作为某些疾病的特殊医学食品，但这些产品在糖尿病（一种主要的心血管危险因素）中的作用尚未得到研究。因此，我们在此研究了一种供人类使用的不同矿物质、维生素和微量元素制剂（MVT）是否会影响实验性糖尿病的严重程度。
对两天大的新生雄性和雌性Wistar大鼠注射100mg/kg链脲佐菌素或其赋形剂以诱导糖尿病。在第4周时，给大鼠喂食MVT制剂或赋形剂，持续8周。在第4周、第8周和第12周进行已确立的糖尿病诊断参数检测，即空腹血糖和口服葡萄糖耐量试验。此外，在第12周测量血清胰岛素和糖化血红蛋白（HbA1c）。
在第4周时，链脲佐菌素处理的雄性和雌性大鼠均出现糖耐量受损。在雄性大鼠中，与未接受糖尿病治疗的赋形剂处理组相比，在第12周时，接受糖尿病治疗的赋形剂处理组空腹血糖和HbA1c显著升高，糖耐量和血清胰岛素降低。MVT治疗使雄性大鼠的所有糖尿病诊断参数均得到显著改善。在雌性大鼠中，链脲佐菌素治疗导致的糖尿病前期样表型较轻，因为与未接受糖尿病治疗的赋形剂处理组相比，在接受糖尿病治疗的赋形剂处理组中，仅在研究结束时糖耐量和HbA1c发生了改变。MVT治疗未能改善链脲佐菌素处理的雌性大鼠的糖尿病诊断参数。
这是首次证明MVT可显著减轻慢性实验性糖尿病雄性大鼠的糖尿病进展。此外，我们证实雌性对链脲佐菌素诱导的糖尿病敏感性较低，且MVT制剂对糖尿病前期状态没有保护作用。这可能提示糖尿病发病机制存在性别差异。
